Seer Inc
SEER
查看详细走势图
1.790USD
+0.040+2.29%
收盘 02/06, 16:00（美东）报价延迟15分钟
99.86M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.29%
5天
-1.65%
1月
-5.29%
6月
-10.95%
今年开始到现在
-2.19%
1年
-20.80%
查看详细走势图
TradingKey Seer Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Seer Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力稳定。当前估值合理，在办公设备行业排名6/7位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.00。中期看，股价处于下降通道。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Seer Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Seer Inc亮点
亮点风险
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
业绩增长期
公司处于发展阶段，最新年度总收入14.17M美元
估值合理
公司最新PB估值0.37，处于3年历史合理位
机构减仓
最新机构持股31.15M股，环比减少21.07%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值79.89K
分析师目标
根据
1
位分析师
买入
评级
3.000
目标均价
+52.28%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Seer Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Seer Inc简介
Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
公司代码SEER
公司Seer Inc
CEOFarokhzad (Omid C)
网址https://seer.bio/
相关品种
